Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer	Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma	Recruiting	Phase 3	2026-07-23		NCT06606730

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
UNICANCER	111

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Cliniques Universitaires Saint Luc Brussels	Brussels	Belgium	1
Institut Gustave Roussy	Villejuif	France	113

Clinical trials